Author:
Zhang Qingyuan,Feng Jifeng,Wang Huaqing,Huang Huiqiang,Zhang Huilai,Li Xiaoqiu,Gao Yuhuan,Song Yongping,Li Zhiming,Bai Ou,Cao Junning,Zhou Hui,Gu Kangsheng,Zhao Shu,Zhao Wenhui,Qin Yan,Li Yajun,Ma Guangyu,Wen Shujuan,Wang Yu,Zhao Peiqi,Guo Wei,Lv Fangfang,Tian Yuyang,Chen Xinrui,Xie Zucheng,Shi Yuankai,
Abstract
Abstract
Purpose
Lymphoma has become a major threat to human health. Fortunately, the diagnosis and treatment of lymphoma have developed rapidly, and research progress has emerged in an endless stream, with new drugs emerging one after another. These results are constantly rewriting guidelines changing clinical practice, need to be popularized and applied more widely.
Methods
This guideline has integrated consensuses reached by the Lymphoma Committee of China Anti-Cancer Association (CACA), based on China's practice, tracking previous results of the most advanced clinical researches, absorbing the latest clinical evidence, and referring to domestic and international lymphoma guidelines.
Results
This holistic integrative guideline of lymphoma introduces the latest progress in the diagnosis and treatment of different subtypes of lymphoma, guide the clinical application of new drugs, standardized and precise management for lymphoma patients.
Conclusions
CACA guidelines for holistic integrative management of lymphoma (version 2022) enhance standardization and precision of the management for lymphoma patients in China.
Publisher
Springer Science and Business Media LLC